Measuring a person’s troponin levels using the Troponin-I blood test can help predict a person’s chances of having a cardiac event in advance. Credit: Lori Greig.

Abbott has received US Food and Drug Administration (FDA) clearance for its Architect Stat High Sensitivity Troponin-I blood test to diagnose heart attacks.

The blood test is said to detect heart attacks several hours earlier than conventional troponin tests, for a faster and more accurate diagnosis.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

A troponin blood test is commonly used to diagnose individuals who visit an emergency room with a suspected heart attack. The levels of troponin-I proteins released from the heart are known to increase in the blood in case of heart muscle damage.

Abbott’s blood test is designed to measure low troponin levels and enable assessment of heart attack within two to four hours of admission.

The company expects that the Architect Stat High Sensitivity Troponin-I blood test will particularly help women, who have lower troponin levels than men.

Abbott Diagnostics global medical and scientific affairs senior medical director Agim Beshiri said: “This important milestone will allow US physicians to utilise the advanced, proven capabilities of this blood test as they evaluate patients suspected of a heart attack.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“As one of the most widely researched high sensitivity troponin tests, this technology could help address several challenges in emergency departments today, including overcrowding and more accurately identifying heart attacks in women.”

The blood test can be used on the company’s fully-automated Architect analyser and in conjunction with additional diagnostic information, including electrocardiogram (ECG), clinical observations and information and patient symptoms.

Abbott will initiate Heart Partnership Program in the US to help hospital care teams implement the blood test into their care pathway.

The blood test has been assessed in around 200 studies throughout Europe and Asia, where it is named High Sensitive Troponin-I.

In April, Abbott reported positive findings from a study, where the Troponin-I blood test was able to predict heart disease risks in those with no symptoms.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact